Uveitis Treatment Market

Uveitis Treatment Market Study by Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungals, and Analgesics from 2024 to 2034

Analysis of Uveitis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Uveitis Treatment Market Outlook (2024 to 2034)

As per a new study published by Fact.MR, the global uveitis treatment market size is estimated at US$ 791 million in 2024 and is projected to expand at a CAGR of 5.8% to reach US$ 1.4 billion by 2034-end.

Increasing prevalence of uveitis in certain countries is attributed to a growing aging population, rising incidence of autoimmune diseases, and improved diagnostic capabilities. As uveitis incidence climbs, demand for effective treatment intensifies.

Uveitis treatment aims to alleviate symptoms and prevent vision loss by managing inflammation in the uvea, the eye's central layer. Common treatment modalities include corticosteroids to reduce inflammation, immunosuppressive medications for severe or persistent cases, and biologics targeting specific immune pathways.

In some instances, surgical interventions like vitrectomy or the implantation of medication delivery devices become necessary. Treatment objectives focus on inflammation reduction, complication prevention, and vision preservation, contingent upon the underlying cause, severity, and type of uveitis.

Key Market Growth Drivers

  • Innovative therapeutic approaches are being developed as a result of significant progress in understanding the etiology of uveitis.
  • Expansion of the uveitis treatment market size is fueled by the introduction of sustained-release medication delivery technologies, including biodegradable microspheres and intravitreal implants.
  • These technologies ensure prolonged drug exposure, enhancing patient compliance by reducing the necessity for systemic drugs or injections.
  • Significant advancements in understanding the pathophysiology of uveitis are fostering the development of novel treatment modalities. Biologic therapies, such as fusion proteins and monoclonal antibodies targeting specific cytokines or cell surface markers, offer opportunities for more effective and personalized therapeutic interventions.
  • Increased funding from pharmaceutical companies and organizations for research and development initiatives aimed at uveitis treatment is driving the exploration of new medicinal agents and treatment strategies.
  • Expansion of the market is further fueled by the proliferation of open-angle glaucoma treatments available through retail pharmacies and the growing presence of such pharmacies in various countries.
Report Attribute Detail
Uveitis Treatment Market Size (2024E) US$ 791 Million
Forecasted Market Value (2034F) US$ 1.4 Billion
Global Market Growth Rate (2024 to 2034) 5.8% CAGR
North America Market Share (2024E) 36.8%
East Asia Market Value (2024E) US$ 117 Million
Corticosteroids Segment Value (2034F) US$ 319.9 Million
Anterior Uveitis Segment Value (2034F) US$ 830 Million
Infectious Uveitis Segment Value (2034F) US$ 1.21 Billion
Key Companies Profiled Sun Pharmaceutical Industries Ltd.; EyePoint Pharmaceuticals, Inc.; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Inflammasome Therapeutics Inc.; Graybug Vision, Inc.; TopiVert Pharma Ltd.; Pfizer Inc.; Bausch Health Companies Inc.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

What is Contributing to Increasing Demand for Uveitis Treatment?

“Advancements in Sustained-Release Drug-Delivery Techniques Lowering Risk of Adverse Effects”

One of the key uveitis treatment market trends is technological advancements in therapeutic techniques, particularly in the development of drug-delivery devices with sustained release. Due to their ability to deliver sustained medication exposure directly to the afflicted eye tissues, these systems incorporating biodegradable microspheres and intravitreal implants offer considerable benefits. Their reduction in the requirement for frequent injections or systemic drugs not only improves patient compliance and convenience but also lowers the possibility of adverse systemic effects.

What Issue is Primarily Hindering Adoption of Uveitis Treatment?

“Rising Concerns Over Immune Suppression and Susceptibility to Infection”

By focusing on certain inflammatory pathways, biological treatments are transforming the management of uveitis but not without risk. Uveitis treatments may suppress the immune system, increasing the susceptibility to infections, especially in individuals with compromised immune systems or underlying medical conditions.

Healthcare providers must meticulously assess the risk-benefit balance of biologics, considering the patient's overall health, severity of their uveitis, and potential side effects. Professionals prioritize the safe and effective management of uveitis by meticulously evaluating these factors and optimizing treatment choices to maximize therapeutic outcomes. However, rising concerns over associated risks are constraining market growth.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

North America is estimated to hold 36.8% revenue share of the global market in 2024. Demand for uveitis treatment in East Asia is projected to rise at 7% CAGR from 2024 to 2034.

What Has Made the United States a Lucrative Market for Uveitis Treatment Providers?

“Targeted Approaches to Modulate Specific Inflammatory Pathways Associated with Uveitis”

Attribute United States
Market Value (2024E) US$ 214 Million
Growth Rate (2024 to 2034) 5% CAGR
Projected Value (2034F) US$ 347 Million

In the United States, the therapeutic options for uveitis are significantly expanding with the introduction of potent medications like biologic therapy and sustained-release drug delivery methods. Biologic treatments, such as fusion proteins and monoclonal antibodies, offer targeted approaches to modulate specific inflammatory pathways associated with uveitis. Compared to conventional immunosuppressive drugs, these treatments enhance patients' outcomes and quality of life by providing a more precise and effective therapeutic alternative.

Why is Demand for Uveitis Treatment Increasing Steadily in Japan?

“Extensive Availability of Specialized Eye Care Facilities”

Attribute Japan
Market Value (2024E) US$ 39 Million
Growth Rate (2024 to 2034) 5.8% CAGR
Projected Value (2034F) US$ 70 Million

Strong healthcare sector in Japan is essential to meeting the rising need for uveitis treatment. People with uveitis have easy access to diagnostic and treatment choices due to the extensive availability of medical services, including specialized eye care facilities. Better patient outcomes result from the swift detection and management of uveitis, which is made possible by increasing access to healthcare resources.

Availability of specialist eye care centers furnished with advanced diagnostic and therapeutic modalities is enabling medical professionals to offer patients with uveitis thorough and efficient care in Japan. All of these factors are contributing to uveitis market growth in the country.

Category-wise Insights

Based on disease, the market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment is poised to hold 57.8% market share in 2024. The significant number of cases of anterior uveitis worldwide is due to its multifactorial nature, which includes autoimmune illnesses, infections, and ocular traumas. The necessity for uveitis therapy is increasing in this segment since untreated cases result in blindness, cataracts, and glaucoma.

Which Treatment Modality is Widely Preferred by Healthcare Providers?

“Greater Effectiveness of Corticosteroids in Reducing Eye Inflammation Than Other Drugs”

Attribute Corticosteroids
Segment Value (2024E) US$ 172.5 Million
Growth Rate (2024 to 2034) 6.4% CAGR
Projected Value (2034F) US$ 319.9 Million

By treatment type, the corticosteroids segment is set to hold 21.8% of the uveitis treatment market share in 2024 and is further projected to account for a 22.9% market share by the end of 2034. Rising demand for corticosteroids is driven by their greater effectiveness in reducing eye inflammation as compared to other drugs.

Patients with uveitis benefit from consumption of corticosteroids because they assist in reducing the immunological response that causes inflammation. Beyond this, corticosteroids are an adaptable therapeutic choice for uveitis since they are given as injections, ocular drops, or oral drugs.

Which Distribution Channel Accounts for Substantial Revenue Generation?

“Hospital Pharmacies Generating High Revenue Due to Large Patient Base”

Attribute Hospital Pharmacies
Segment Value (2024E) US$ 361.9 Million
Growth Rate (2024 to 2034) 5.7% CAGR
Projected Value (2034F) US$ 632.2 Million

Hospital pharmacies occupy a significant share of the market. Uveitis requires ongoing care, leading to a large patient base in hospitals and a consistent demand for uveitis drugs seen by hospital pharmacists. With a growing number of uveitis patients requiring continuous access to prescribed medications, hospitals generate increased revenue from treating this condition. Moreover, hospital pharmacies leverage agreements with specific providers of uveitis medicines, enabling them to procure these drugs at reasonable costs and enhance their earnings from sales.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competitive Landscape

Key players in the uveitis treatment market are using effective pricing strategies. Companies need to take into account several variables such as manufacturing costs, market demand, rival pricing, and reimbursement procedures. Sustaining corporate development and maintaining market share necessitates finding a balance between profitability and competitive pricing.

  • In January 2024, Tarsier Pharma obtained approval from the United States FDA under the Special Protocol Assessment (SPA) for the Tarsier-04 Phase 3 trial of the TRS01 ophthalmic solution, targeting non-infectious uveitis, including uveitic glaucoma.
  • In October 2021, the FDA greenlit XIPER, or triamcinolone acetonide injectable suspension, for suprachoroidal use, addressing macular edema linked with uveitis.
  • In December 2020, Alimera Sciences Europe Ltd. introduced ILUVIEN in the Netherlands, targeting diabetic macular edema (DME) and non-infectious posterior segment uveitis (NIPU), aiming for geographic expansion to reach more physicians and patients.

Fact.MR provides detailed information about the price points of prominent players in the uveitis treatment market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Uveitis Treatment Market Research

  • By Treatment :

    • Corticosteroids
    • Immunosuppressants
    • Monoclonal Antibodies
    • Cycloplegic Agents
    • Antibiotics
    • Antivirals
    • Antifungals
    • Analgesics
  • By Disease :

    • Anterior Uveitis
    • Posterior Uveitis
    • Intermediate Uveitis
    • Panuveitis
  • By Cause :

    • Infectious Uveitis
    • Non-infectious Uveitis
  • By Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Drug Stores
  • By Region :

    • North America
    • Western Europe
    • Eastern Europe
    • Latin America
    • East Asia
    • South Asia & Pacific
    • Middle East & Africa

Table of Content

1. Executive Summary

2. Industry Introduction, including Taxonomy and Market Definition

3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments

4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections

5. Pricing Analysis

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    6.1. Treatment

    6.2. Disease

    6.3. Cause

    6.4. Distribution Channel

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Treatment

    7.1. Corticosteroids

    7.2. Immunosuppressants

    7.3. Monoclonal Antibodies

    7.4. Cycloplegic Agents

    7.5. Antibiotics

    7.6. Antivirals

    7.7. Antifungals

    7.8. Analgesics

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Disease

    8.1. Anterior Uveitis

    8.2. Posterior Uveitis

    8.3. Intermediate Uveitis

    8.4. Panuveitis

9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Cause

    9.1. Infectious Uveitis

    9.2. Non-infectious Uveitis

10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel

    10.1. Hospital Pharmacies

    10.2. Retail Pharmacies

    10.3. Online Pharmacies

    10.4. Drug Stores

11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region

    11.1. North America

    11.2. Latin America

    11.3. Western Europe

    11.4. Eastern Europe

    11.5. East Asia

    11.6. South Asia & Pacific

    11.7. Middle East & Africa

12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries

19. Sales Forecast 2024 to 2034 by Treatment, Disease, Cause, Distribution Channel, and Region for 30 Countries

20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard

21. Company Profile

    21.1. Sun Pharmaceutical Industries Ltd.

    21.2. EyePoint Pharmaceuticals, Inc.

    21.3. Ophthotech Corporation

    21.4. Regeneron Pharmaceuticals, Inc.

    21.5. Takeda Pharmaceutical Company Limited

    21.6. Inflammasome Therapeutics Inc.

    21.7. Graybug Vision, Inc.

    21.8. TopiVert Pharma Ltd.

    21.9. Pfizer Inc.

    21.10. Bausch Health Companies Inc.

22. Assumptions and Acronyms Used

23. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 02: Global Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 04: Global Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 05: Global Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 07: Global Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 08: Global Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 10: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 11: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023

Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034

Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034

Table 16: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 17: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 19: North America Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 20: North America Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 22: North America Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 23: North America Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 25: North America Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 26: North America Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 28: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 29: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 30: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 31: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 32: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 34: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 35: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 37: Latin America Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 38: Latin America Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 40: Latin America Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 41: Latin America Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 42: Latin America Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 43: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 44: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 45: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 46: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 47: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 49: Western Europe Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 50: Western Europe Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 51: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 52: Western Europe Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 53: Western Europe Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 54: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 55: Western Europe Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 56: Western Europe Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 57: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 58: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 59: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 60: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 61: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 62: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 63: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 64: Eastern Europe Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 65: Eastern Europe Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 66: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 67: Eastern Europe Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 68: Eastern Europe Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 69: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 70: Eastern Europe Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 71: Eastern Europe Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 72: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 73: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 74: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 75: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 76: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 77: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 78: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 79: East Asia Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 80: East Asia Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 81: East Asia Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 82: East Asia Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 83: East Asia Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 84: East Asia Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 85: East Asia Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 86: East Asia Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 87: East Asia Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 88: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 89: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 90: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 91: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 92: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 93: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 94: South Asia & Pacific Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 95: South Asia & Pacific Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 96: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 97: South Asia & Pacific Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 98: South Asia & Pacific Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 99: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 100: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 101: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 102: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 103: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 104: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 105: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

Table 106: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023

Table 107: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034

Table 108: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034

Table 109: MEA Market Value (US$ Mn) Analysis, by Treatment, 2019 to 2023

Table 110: MEA Market Value (US$ Mn) Analysis, by Treatment, 2024 to 2034

Table 111: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2024 to 2034

Table 112: MEA Market Value (US$ Mn) Analysis, by Disease, 2019 to 2023

Table 113: MEA Market Value (US$ Mn) Analysis, by Disease, 2024 to 2034

Table 114: MEA Market Value (US$ Mn) Opportunity Analysis, by Disease, 2024 to 2034

Table 115: MEA Market Value (US$ Mn) Analysis, by Cause, 2019 to 2023

Table 116: MEA Market Value (US$ Mn) Analysis, by Cause, 2024 to 2034

Table 117: MEA Market Value (US$ Mn) Opportunity Analysis, by Cause, 2024 to 2034

Table 118: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023

Table 119: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034

Table 120: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034

Figure 05: Global Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 06: Global Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 07: Global Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 08: Global Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 09: Global Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 10: Global Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 11: Global Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 12: Global Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 13: Global Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 14: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 15: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 16: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 17: Global Market Share and BPS Analysis by Region, 2024 & 2034

Figure 18: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034

Figure 19: Global Market Attractiveness Analysis by Region, 2024 to 2034

Figure 20: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 21: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 22: North America Market Value Y-o-Y Growth and Forecast, 2034

Figure 23: North America Market Incremental $ Opportunity, 2024 to 2034

Figure 24: North America Market Share Analysis by Country, 2024 & 2034

Figure 25: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 26: North America Market Attractiveness Analysis by Country, 2024 to 2034

Figure 27: North America Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 28: North America Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 29: North America Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 30: North America Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 31: North America Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 32: North America Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 33: North America Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 34: North America Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 35: North America Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 36: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 37: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 38: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 39: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 40: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 41: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 42: Latin America Market Incremental $ Opportunity, 2024 to 2034

Figure 43: Latin America Market Share Analysis by Country, 2024 & 2034

Figure 44: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 45: Latin America Market Attractiveness Analysis by Country, 2024 to 2034

Figure 46: Latin America Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 47: Latin America Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 48: Latin America Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 49: Latin America Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 50: Latin America Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 51: Latin America Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 52: Latin America Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 53: Latin America Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 54: Latin America Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 55: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 56: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 57: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 58: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 59: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 60: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 61: Western Europe Market Incremental $ Opportunity, 2024 to 2034

Figure 62: Western Europe Market Share Analysis by Country, 2024 & 2034

Figure 63: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 64: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034

Figure 65: Western Europe Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 66: Western Europe Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 67: Western Europe Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 68: Western Europe Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 69: Western Europe Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 70: Western Europe Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 71: Western Europe Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 72: Western Europe Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 73: Western Europe Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 74: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 75: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 76: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 77: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 78: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 79: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 80: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034

Figure 81: Eastern Europe Market Share Analysis by Country, 2024 & 2034

Figure 82: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 83: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034

Figure 84: Eastern Europe Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 85: Eastern Europe Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 86: Eastern Europe Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 87: Eastern Europe Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 88: Eastern Europe Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 89: Eastern Europe Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 90: Eastern Europe Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 91: Eastern Europe Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 92: Eastern Europe Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 93: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 94: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 95: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 96: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 97: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 98: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 99: East Asia Market Incremental $ Opportunity, 2024 to 2034

Figure 100: East Asia Market Share Analysis by Country, 2024 & 2034

Figure 101: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 102: East Asia Market Attractiveness Analysis by Country, 2024 to 2034

Figure 103: East Asia Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 104: East Asia Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 105: East Asia Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 106: East Asia Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 107: East Asia Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 108: East Asia Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 109: East Asia Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 110: East Asia Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 111: East Asia Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 112: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 113: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 115: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 116: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 117: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 118: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034

Figure 119: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034

Figure 120: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 121: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034

Figure 122: South Asia & Pacific Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 123: South Asia & Pacific Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 124: South Asia & Pacific Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 125: South Asia & Pacific Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 126: South Asia & Pacific Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 127: South Asia & Pacific Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 128: South Asia & Pacific Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 129: South Asia & Pacific Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 130: South Asia & Pacific Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 131: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 132: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 133: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Figure 134: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023

Figure 135: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034

Figure 136: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034

Figure 137: MEA Market Incremental $ Opportunity, 2024 to 2034

Figure 138: MEA Market Share Analysis by Country, 2024 & 2034

Figure 139: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034

Figure 140: MEA Market Attractiveness Analysis by Country, 2024 to 2034

Figure 141: MEA Market Share and BPS Analysis by Treatment, 2024 & 2034

Figure 142: MEA Market Y-o-Y Growth Projections by Treatment, 2024 to 2034

Figure 143: MEA Market Attractiveness Analysis by Treatment, 2024 to 2034

Figure 144: MEA Market Share and BPS Analysis by Disease, 2024 & 2034

Figure 145: MEA Market Y-o-Y Growth Projections by Disease, 2024 to 2034

Figure 146: MEA Market Attractiveness Analysis by Disease, 2024 to 2034

Figure 147: MEA Market Share and BPS Analysis by Cause, 2024 & 2034

Figure 148: MEA Market Y-o-Y Growth Projections by Cause, 2024 to 2034

Figure 149: MEA Market Attractiveness Analysis by Cause, 2024 to 2034

Figure 150: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034

Figure 151: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034

Figure 152: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

How big is the uveitis treatment market in 2024?

The global market for uveitis treatment is estimated at US$ 791 million in 2024.

What are the projections for the global market by 2034?

Worldwide revenue from uveitis treatment is projected to reach US$ 1.4 billion by 2034-end.

How fast is the market for uveitis treatment forecasted to expand?

The uveitis treatment market is projected to advance at a CAGR of 5.8%.

What are the projections for the market in East Asia?

The East Asia market is estimated at US$ 117 million in 2024 and is projected to increase at 7% CAGR thereafter.

Who are the leading players in the uveitis treatment industry?

Graybug Vision, Inc., TopiVert Pharma Ltd., Pfizer Inc., and Ophthotech Corporation are some of the leading companies in the market.

At what pace is the market projected to grow in South Korea?

The market in South Korea is projected to expand at a CAGR of 9.4% through 2034.

Which type of uveitis treatment is widely popular?

Worldwide demand for corticosteroids is projected to ascend at 6.4% through 2034.

- Also of Interest -

Eye Health Supplements Market

Eye Health Supplements Market Analysis by Lutein & Zeaxanthin, Omega-3 Fatty Acids, Antioxidants, Coenzyme Q10, Flavonoids, Alpha-lipoic Acid, Astaxanthin, and Others from 2023 to 2033

Dry Eye Syndrome Treatment Market

Dry Eye Syndrome Treatment Market Study by Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements, and Others from 2024 to 2034

Uveitis Treatment Market

Schedule a Call